Thus, most natural proteins administered as therapeutics to patients have suboptimal properties for treating the target disease. Natural proteins are not only less efficacious and less safe than ...

Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...

Natural IgMs are potential therapeutics. Clinical trials to treat multiple sclerosis with human natural IgM are underway.

Biotechnology company RubrYc Therapeutics, Inc., founded in 2017 ... designed to present a specific epitope while retaining its natural conformation and motion present in the native target ...

Neural Reactive Natural IgMs & the Nature of Neural Surface Antigens How B cells are activated to secrete antibodies that recognize self-antigens of the nervous system remains unknown. The ...